B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000936104.91195.3e |
| _version_ | 1827332250378698752 |
|---|---|
| author | P. Musto M.C. Minnema W.W.H. Roeloffzen A. Capra B. van der Holt A. Juul Vangsted A. Broyl F. Schjesvold T. Lund T. Silkjaer R. Benjamin M. Grasso K. Lung Wu J. Caers M. Cavo R. Hájek B. Bruno A. Gadisseur G. Pietrantuono M. Offidani L. Pour P. Sonneveld M. Boccadoro N. van de Donk |
| author_facet | P. Musto M.C. Minnema W.W.H. Roeloffzen A. Capra B. van der Holt A. Juul Vangsted A. Broyl F. Schjesvold T. Lund T. Silkjaer R. Benjamin M. Grasso K. Lung Wu J. Caers M. Cavo R. Hájek B. Bruno A. Gadisseur G. Pietrantuono M. Offidani L. Pour P. Sonneveld M. Boccadoro N. van de Donk |
| author_sort | P. Musto |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:56:17Z |
| format | Article |
| id | doaj.art-a78ccd101bf74f0b9acb65bbb68a6fcd |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:56:17Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-a78ccd101bf74f0b9acb65bbb68a6fcd2024-03-03T03:59:02ZengWileyHemaSphere2572-92412023-05-017S25510.1097/01.HS9.0000936104.91195.3e202305002-00013B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARSP. Musto0M.C. Minnema1W.W.H. Roeloffzen2A. Capra3B. van der Holt4A. Juul Vangsted5A. Broyl6F. Schjesvold7T. Lund8T. Silkjaer9R. Benjamin10M. Grasso11K. Lung Wu12J. Caers13M. Cavo14R. Hájek15B. Bruno16A. Gadisseur17G. Pietrantuono18M. Offidani19L. Pour20P. Sonneveld21M. Boccadoro22N. van de Donk231 Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, and Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari, Italy2 University Medical Center Utrecht, Department of Hematology, Utrecht University, Utrecht, the Netherlands3 Department of Hematology, University Medical Center Groningen, University Groningen, Groningen, the Netherlands4 Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy5 HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands6 Dept. Hematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark7 Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands8 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway9 Odense Hospital, Odense, Denmark10 Aarhus University Hospital, Aarhus, Denmark11 King’s College Hospital, London, United Kingdom12 Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy13 Department of Hematology, ZNA Stuivenberg, Antwerp, Belgium14 Department of Hematology, CHU Liege15 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy16 Department of Hematooncology, University Hospital Ostrava and Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic17 Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy18 Department of Haematology, Antwerp University Hospital, Edegem, Belgium19 Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), Rionero in Vulture, Italy20 AOU Ospedali Riuniti di Ancona, Ancona, Italy21 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic22 Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, the Netherlands4 Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy23 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlandshttp://journals.lww.com/10.1097/01.HS9.0000936104.91195.3e |
| spellingShingle | P. Musto M.C. Minnema W.W.H. Roeloffzen A. Capra B. van der Holt A. Juul Vangsted A. Broyl F. Schjesvold T. Lund T. Silkjaer R. Benjamin M. Grasso K. Lung Wu J. Caers M. Cavo R. Hájek B. Bruno A. Gadisseur G. Pietrantuono M. Offidani L. Pour P. Sonneveld M. Boccadoro N. van de Donk B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS HemaSphere |
| title | B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS |
| title_full | B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS |
| title_fullStr | B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS |
| title_full_unstemmed | B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS |
| title_short | B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS |
| title_sort | b03 carfilzomib and lenalidomide for primary plasma cell leukemia final results of the prospective phase 2 emn12 hovon 129 study for patients aged ≥66 years |
| url | http://journals.lww.com/10.1097/01.HS9.0000936104.91195.3e |
| work_keys_str_mv | AT pmusto b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT mcminnema b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT wwhroeloffzen b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT acapra b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT bvanderholt b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT ajuulvangsted b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT abroyl b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT fschjesvold b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT tlund b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT tsilkjaer b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT rbenjamin b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT mgrasso b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT klungwu b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT jcaers b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT mcavo b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT rhajek b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT bbruno b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT agadisseur b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT gpietrantuono b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT moffidani b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT lpour b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT psonneveld b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT mboccadoro b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years AT nvandedonk b03carfilzomibandlenalidomideforprimaryplasmacellleukemiafinalresultsoftheprospectivephase2emn12hovon129studyforpatientsaged66years |